Handok to launch combined anti-diabetic drug.

Published: 2005-10-24 06:56:00

Updated: 2005-10-24 06:56:00

Handok has launched Amaryl-M, a combined anti-diabetic drug with Amaryl (glimepiride) and metformin, which boosts to simulate Insulin secretion and at the same time to enhance an Insulin sensitivity.

Two dosage forms are introduced, namely, Amaryl M 1/250 (1mg of glimepiride plus metformin 250...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK